Lexaria Bioscience (LEXX) Competitors $1.41 -0.12 (-7.58%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. MGNX, VIRI, VXRT, EDIT, ELUT, RENB, TLSA, ADVM, COYA, and CHRSShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include MacroGenics (MGNX), Virios Therapeutics (VIRI), Vaxart (VXRT), Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), Adverum Biotechnologies (ADVM), Coya Therapeutics (COYA), and Coherus BioSciences (CHRS). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. MacroGenics Virios Therapeutics Vaxart Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Coya Therapeutics Coherus BioSciences MacroGenics (NASDAQ:MGNX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Do analysts recommend MGNX or LEXX? MacroGenics presently has a consensus price target of $7.38, indicating a potential upside of 599.05%. Lexaria Bioscience has a consensus price target of $7.00, indicating a potential upside of 395.05%. Given MacroGenics' higher possible upside, equities analysts clearly believe MacroGenics is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, MGNX or LEXX? MacroGenics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Do insiders and institutionals have more ownership in MGNX or LEXX? 96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer MGNX or LEXX? In the previous week, Lexaria Bioscience had 1 more articles in the media than MacroGenics. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.67 beat Lexaria Bioscience's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media. Company Overall Sentiment MacroGenics Positive Lexaria Bioscience Neutral Is MGNX or LEXX more profitable? MacroGenics has a net margin of -69.07% compared to Lexaria Bioscience's net margin of -1,473.04%. Lexaria Bioscience's return on equity of -88.88% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Lexaria Bioscience -1,473.04%-88.88%-83.59% Does the MarketBeat Community believe in MGNX or LEXX? MacroGenics received 419 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 62.10% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42662.10% Underperform Votes26037.90% Lexaria BioscienceOutperform Votes7100.00% Underperform VotesNo Votes Which has preferable valuation and earnings, MGNX or LEXX? Lexaria Bioscience has lower revenue, but higher earnings than MacroGenics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$148.34M0.45-$9.06M-$1.08-0.98Lexaria Bioscience$496.92K49.95-$5.80M-$0.50-2.83 SummaryMacroGenics beats Lexaria Bioscience on 11 of the 19 factors compared between the two stocks. Remove Ads Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.82M$6.44B$5.33B$7.16BDividend YieldN/A2.85%4.87%4.06%P/E Ratio-2.836.8322.9417.50Price / Sales49.95190.01357.9385.03Price / CashN/A65.6738.1634.64Price / Book2.955.656.263.82Net Income-$5.80M$142.17M$3.21B$247.19M7 Day Performance-17.79%-11.22%-7.86%-7.19%1 Month Performance16.86%-14.31%-2.83%-9.97%1 Year Performance-55.67%-18.16%3.74%-7.26% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.3079 of 5 stars$1.41-7.6%$7.00+395.0%-55.1%$24.82M$496,923.00-2.837Upcoming EarningsNews CoverageMGNXMacroGenics3.7234 of 5 stars$1.96-1.8%$7.63+289.0%-91.6%$123.02M$148.34M-1.24430Gap DownVIRIVirios Therapeutics0.4067 of 5 stars$6.33-7.3%$3.00-52.6%+723.2%$121.90MN/A-23.445VXRTVaxart2.4736 of 5 stars$0.51-0.7%$4.00+680.3%-69.2%$116.61M$28.70M-1.25120EDITEditas Medicine4.0345 of 5 stars$1.39+6.1%$6.83+391.6%-83.7%$115.34M$32.31M-0.54230ELUTElutia3.9644 of 5 stars$2.81-3.8%$9.00+220.3%-7.9%$114.47M$24.38M-1.08180Gap UpRENBRenovaro0.6969 of 5 stars$0.72+2.6%N/A-83.0%$114.04MN/A-0.7720News CoverageGap UpTLSATiziana Life Sciences0.7571 of 5 stars$1.08-2.7%N/A+133.7%$113.83MN/A0.008Gap DownADVMAdverum Biotechnologies4.2695 of 5 stars$5.40+5.9%$27.83+415.4%-70.5%$112.33M$1M-0.90190News CoveragePositive NewsGap DownCOYACoya Therapeutics2.0717 of 5 stars$6.65-0.4%$17.00+155.6%-38.4%$111.22M$3.55M-10.236CHRSCoherus BioSciences3.0157 of 5 stars$0.95-7.6%$5.38+464.5%-65.7%$110.35M$266.96M-11.90330Gap Down Remove Ads Related Companies and Tools Related Companies MGNX Competitors VIRI Competitors VXRT Competitors EDIT Competitors ELUT Competitors RENB Competitors TLSA Competitors ADVM Competitors COYA Competitors CHRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LEXX Stock Free LEXX Stock Alerts